All In Biotech

Drug Trial Radar · NCT02234882

Study on Pharmacokinetics

Effect of BMS-663068 on the Pharmacokinetics of Rosuvastatin

Last checked: Nov 19, 2026Latest source record: Apr 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Sep 5, 2014

Primary completion

Oct 31, 2014

Study completion Oct 31, 2014

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Sep 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of the coadministration of multiple doses of BMS-663068 on the systemic exposure of rosuvastatin.

Conditions

  • HIV Infections

Interventions

  • RosuvastatinDrug

  • BMS-663068Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax) of rosuvastatinTime frame: Days 1 through 13
  2. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC[INF]) of rosuvastatinTime frame: Days 1 through 13

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.